Free tools Windows power users keep installed
One-click scans. No signup required.
Medical cyclotrons could reduce the risk of technetium-99m (Tc-99m) shortages, but they are not a universal replacement for the molybdenum-99 (Mo-99) generator system. A cyclotron can make Tc-99m directly, offering a second supply route if reactor-produced Mo-99 becomes unavailable. Whether that route works at a particular site depends on beam energy and particle type, target design, irradiation capacity, chemical processing, purification, quality control, trained staff, radiation protection, waste handling and regulatory approval.
Tc-99m remains central to nuclear-medicine imaging. The practical answer is therefore supply diversification: cyclotrons can complement generators and preserve access to established Tc-99m radiopharmaceuticals, while reactor production and domestic Mo-99 projects continue to underpin much of the existing system.
As an Amazon Associate I earn from qualifying purchases.
Why a Tc-99m shortage affects routine imaging
Tc-99m is used in a broad range of diagnostic nuclear-medicine procedures. The U.S. National Nuclear Security Administration (NNSA) says more than 40,000 U.S. medical procedures use Tc-99m every day (NNSA, September 8, 2025). Interruptions therefore affect scheduled scans, hospital radiopharmacies and patients who may have few practical alternatives.
Recommended Free Tools
The established supply chain starts with reactor-produced Mo-99. Mo-99 is shipped to facilities in generator form, where it decays to Tc-99m that can then be eluted and used to label radiopharmaceuticals. This arrangement links imaging availability to reactor operation, target production, processing, transport and the short-lived isotope logistics that follow.
#1 Best Overall
That dependence became visible when two overseas production reactors shut down at the same time in 2024—one scheduled shutdown and one unscheduled event. NNSA described the combination as a major global Mo-99 shortage with significant effects in the United States (NNSA, September 8, 2025).
How cyclotrons make Tc-99m directly
A medical cyclotron accelerates charged particles and directs them at a prepared target. The target, beam conditions and irradiation schedule are selected to produce Tc-99m. The irradiated target then has to be opened, chemically processed and purified so the product meets the chemical purity and specific-activity requirements needed to label molecules for patient imaging.
The International Atomic Energy Agency (IAEA) treats this as a complete production chain rather than a single machine purchase. Its technical report covers target preparation, irradiation at high beam currents, target processing and recovery, and separation and purification (IAEA, Cyclotron Based Production of Technetium-99m, 2017).
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Rank #2
- Select and qualify the target. The target design must tolerate the intended beam and permit reliable recovery of the product after irradiation.
- Schedule an irradiation. The facility must have suitable cyclotron energy, particle type, beam current and shielding for the Tc-99m process.
- Irradiate at the validated settings. High-current operation can increase production potential, but it also raises heat-load, radiation-protection and equipment-management demands.
- Transfer the activated target safely. Target handling, remote operations and contamination controls are part of the production system.
- Process and purify the material. Chemical separation removes unwanted radionuclides and target materials. Recovery steps can be needed to make the process practical and repeatable.
- Release only material that passes testing. Radiochemical and chemical purity, identity, activity and other product-quality checks must satisfy the applicable specification before a radiopharmaceutical is prepared for clinical use.
The point of the cyclotron route is that Tc-99m is produced at or near the imaging network instead of being obtained only by waiting for Mo-99 to decay inside a generator. The IAEA says such alternatives could allow continued use of existing Tc-99m radiopharmaceuticals if another shortage occurs: “Such alternative methods would enable the continued use of all existing radiopharmaceuticals designed for 99mTc in nuclear medicine, for example, as diagnostic imaging agents, if another shortage should arise” (IAEA, 2017).
Why the global cyclotron count is not a ready-made backup network
The IAEA reported more than 1,300 cyclotron facilities worldwide in 2021 and said many facilities devote about 15 to 20 hours per week to radionuclide production (IAEA, Alternative Radionuclide Production with a Cyclotron, 2021). Those figures show that a substantial installed base exists, and spare capacity at medical cyclotron centres is one reason the IAEA examined alternative production.
They do not mean that 1,300 facilities can immediately make clinical-grade Tc-99m. A facility may be configured for a different energy range or particle type, have no suitable target station, lack hot-cell processing equipment, or have insufficient space for an additional production line. Staff may be trained for fluorine-18 or other established products but not for Tc-99m target chemistry and purification. Quality systems, automation, radiation protection, radioactive-waste arrangements and licensing can be equally decisive.
Capabilities that determine feasibility
| Capability | Why it matters for direct Tc-99m |
|---|---|
| Cyclotron energy and particle type | The machine must provide the beam conditions required by the selected production method; a cyclotron configured for another purpose may not qualify. |
| Targetry | The target must withstand irradiation, support heat removal and allow safe, reproducible recovery of the product. |
| Processing and purification | Post-irradiation chemistry must remove impurities and deliver material with suitable chemical purity and specific activity. |
| Hot cells, automation and shielding | Remote handling and containment reduce exposure and contamination risks during transfer and processing. |
| Quality control | Testing and documented release procedures are required before material can enter a clinical radiopharmacy workflow. |
| People and compliance | Specialist operators, radiation-protection staff, waste systems and regulatory approvals determine whether production can run legally and reliably. |
Cyclotron production versus the Mo-99 generator pathway
The two approaches solve different parts of the supply problem. Reactor production creates the parent isotope that generators distribute; cyclotron production creates Tc-99m directly. A resilient system can use both rather than treating one as an automatic substitute for the other.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minute| Question | Mo-99 generator pathway | Direct cyclotron pathway |
|---|---|---|
| What is produced first? | Reactor-produced Mo-99 | Tc-99m produced by irradiating a target in a cyclotron |
| Where does the decay step occur? | Inside a generator after Mo-99 is shipped to the user | There is no Mo-99-to-Tc-99m generator step; Tc-99m is recovered during target processing |
| Primary dependencies | Reactor availability, Mo-99 processing, transport and generator distribution | Suitable cyclotron beam conditions, targetry, processing, purification, quality control and regulatory systems |
| Clinical compatibility | Existing Tc-99m radiopharmaceutical workflows | The IAEA says the alternative route could support continued use of existing radiopharmaceuticals designed for Tc-99m, provided the product meets required specifications |
| Best role in a shortage plan | Core established supply route | Complementary local or regional source that can diversify supply |
The table does not imply that every cyclotron site can replace a generator. It shows why the most defensible policy is redundancy: maintain the established route while building qualified alternatives where the technical and regulatory conditions make them viable.
What the recent U.S. supply efforts say about timing
U.S. agencies have been pursuing domestic Mo-99 production alongside interest in alternative routes. In the September 8, 2025 NNSA release, Acting Deputy Administrator for Defense Nuclear Nonproliferation Kasia Mendelsohn said: “We’ve spent years working with U.S. companies to reshore Mo-99 production using advanced technology that doesn’t require weapons-usable nuclear material. But NNSA hasn’t been alone in its efforts. Other agencies and departments are a big part of aiding the rebirth of this innovative U.S. industry.” (NNSA, September 8, 2025)
That release described SHINE’s Janesville facility as approximately 75% complete at that time. It also discussed a proposed $10 Medicare add-on for radiopharmaceuticals derived from domestically produced Mo-99 beginning January 1, 2026. Because the payment was described in a proposed rule, it should not be treated as final policy without checking the current Centers for Medicare & Medicaid Services status.
On April 9, 2026, NNSA announced a conditional commitment for a loan of up to $263 million for SHINE’s Chrysalis facility through the Department of Energy’s Office of Energy Dominance Financing (NNSA, April 9, 2026). The announcement said technical, legal, environmental and financial conditions still had to be met before definitive financing documents and funding, and that production was expected after additional completion. The 75% construction figure and the conditional loan are dated project statuses, not proof that a facility is operating today.
How a hospital or regional network should assess readiness
A site considering direct production should evaluate the complete operating model, not simply ask whether a cyclotron is present.
Best Value
- Map the clinical demand. Identify the number and timing of Tc-99m studies, the radiopharmaceuticals used and the periods when generator deliveries are most vulnerable.
- Audit the machine. Confirm energy range, particle type, beam-current capability, target ports, maintenance history and available production windows.
- Design the target and processing line. Include target loading, cooling, transfer, hot-cell operations, chemical separation, purification and recovery.
- Build the quality system. Define validated methods, calibration, sterility or endotoxin controls where applicable, batch records, deviation handling and release authority.
- Secure trained personnel. Operators, radiochemists, quality specialists, radiation-protection experts and maintenance staff must cover routine and emergency operations.
- Confirm licensing and waste routes. Production may require changes to radioactive-material authorizations, facility shielding, environmental controls and waste contracts.
- Plan distribution. Tc-99m’s short-lived nature makes scheduling, transport time and backup arrangements central to the value of a local or regional source.
- Run qualification before relying on it. Demonstrate reproducible production, purification, testing and clinical radiopharmacy compatibility before counting the route as shortage capacity.
What cyclotrons cannot yet prove
Neither of the cited IAEA reports provides a defensible universal number for how much of a future shortage existing cyclotrons could cover. The facility count and weekly radionuclide-production time are not measures of Tc-99m capacity. They do not reveal how many sites have the right energy, targets, chemistry, staff or licenses.
The documents also do not establish a general cost or production-yield comparison between cyclotron-made Tc-99m and reactor-derived supply. Costs will depend on capital equipment, target consumption, labor, maintenance, quality systems, waste, transport and the scale of operation. A policy decision should therefore use a site-specific business and resilience analysis rather than a claimed universal price advantage.
What a realistic shortage strategy looks like
A practical strategy has three layers. First, keep the reactor-and-generator system reliable through diversified reactors, processing capacity and logistics. Second, develop domestic or regional Mo-99 projects so one overseas disruption does not remove most supply. Third, qualify direct cyclotron production at selected medical centres where the equipment, staffing and regulatory framework can support dependable output.
That layered approach also clarifies the role of cyclotrons during an emergency. A qualified site might provide a local stream of Tc-99m while generators are delayed, but an unprepared site cannot become a supplier merely because its accelerator has spare hours. Production, purification, release testing and distribution must all work together.
Further reading for technical teams
The IAEA paperback Cyclotron Based Production of Technetium-99m (ISBN 978-92-0-102916-4) is aimed at scientists, cyclotron technologists, facility managers and graduate students. It provides the detailed technical treatment of targets, irradiation, processing and purification that a general explainer cannot replace. Check the IAEA edition and current availability before purchasing.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
